Alnylam Pharmaceuticals | ALNY - 贷款资金



金融业
股票价格
USD
资产
USD 5.56B
现金及等价物
USD 1.71B
销售成本
USD 298.45M
流动资产
USD 4.62B
流动负债
USD 1.51B
债务
USD 1.27B
EBIT
USD 112.6M
EBITDA
USD 245.34M
员工
2.23K
EPS每股收益
USD 1.84
股本和储备
USD 1.35B
销售毛利
USD 992.69M
债务利息支出
USD 82.05M
利息收入
USD 26.6M
贷款资金
USD 2.47B
市值
USD 28.59B
净收入
USD 164.49M
营业费用
USD 1.06B
营业利润
USD 112.6M
普通股股本
USD 133.73M
PE价格收益
75.64
税前利润
USD 177.81M
销售收入
USD 1.29B
销售和管理费用
USD 347.92M
股票
USD 97.11M
贸易债权人
USD 108.02M
应收帐款人
USD 912.74M


贷款资金 更改 日
Acadia Pharmaceuticals USD 0 0 2025-03
Agios Pharmaceuticals USD 1.06M 0 2022-09
Alnylam Pharmaceuticals USD 2.47B 6.56M 2026-06
Amgen USD 51.86B 27M 2026-06
Arrowhead Research USD 824.07M 401.34M 2026-06
BioCryst Pharmaceuticals USD 395.4M 203K 2026-06
BioMarin Pharmaceutical USD 3.53B 2.1B 2026-06
Incyte USD 28.42M 994K 2026-06
Ionis Pharmaceuticals USD 1.91B 6.62M 2026-06
Moderna USD 597M 6M 2026-06
Neurocrine Biosciences USD 169.5M 500K 2023-03
Novartis USD 37.45B 7.86B 2026-03
PTC Therapeutics USD 535.52M 248.58M 2026-06
Regeneron Pharmaceuticals USD 1.99B 400K 2026-06
Sangamo BioSciences USD 0 0 2022-06
Sanofi EUR 12.3B 3.42B 2026-03
Sarepta Therapeutics USD 847.62M 9.46M 2026-06
Takeda JPY 4.42T 50.32B 2026-06
Tectonic Therapeutic USD 17K 26K 2026-03
Ultragenyx Pharmaceutical USD 1.13B 19M 2026-03
Vertex Pharmaceuticals USD 106.7M 4.7M 2025-12
Xencor USD 77.54M 4.59M 2026-06